HTL 18318

Drug Profile

HTL 18318

Alternative Names: HTL 0018318; HTL18318

Latest Information Update: 23 Feb 2017

Price : $50

At a glance

  • Originator Heptares Therapeutics
  • Class Antidementias; Antipsychotics; Nootropics; Small molecules
  • Mechanism of Action Muscarinic M1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Cognition disorders

Most Recent Events

  • 23 Feb 2017 Heptares Therapeutics plans a clinical trial for Alzheimer's-disease (In volunteers) in Netherlands (NTR6195)
  • 01 Jan 2017 Heptares Therapeutics completes a phase I trial in Cognition disorders (In volunteers) in United Kingdom (PO, Capsule and Liquid) (NCT02958696)
  • 07 Apr 2016 HTL 18318 licensed to Allergan Pharmaceuticals worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top